- Home
- HUSA vs NERV Comparison
HUSA vs NERV Comparison
Compare HUSA & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUSA
- NERV
- Stock Information
- Founded
- HUSA N/A
- NERV 2007
- Country
- HUSA United States
- NERV United States
- Employees
- HUSA N/A
- NERV N/A
- Industry
- HUSA Oil & Gas Production
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- HUSA Energy
- NERV Health Care
- Exchange
- HUSA Nasdaq
- NERV Nasdaq
- Market Cap
- HUSA 9.6M
- NERV 10.3M
- IPO Year
- HUSA N/A
- NERV 2014
- Fundamental
- Price
- HUSA $0.60
- NERV $1.75
- Analyst Decision
- HUSA
- NERV Hold
- Analyst Count
- HUSA 0
- NERV 1
- Target Price
- HUSA N/A
- NERV $5.00
- AVG Volume (30 Days)
- HUSA 296.6K
- NERV 18.7K
- Earning Date
- HUSA 05-14-2025
- NERV 05-05-2025
- Dividend Yield
- HUSA N/A
- NERV N/A
- EPS Growth
- HUSA N/A
- NERV N/A
- EPS
- HUSA N/A
- NERV 0.19
- Revenue
- HUSA $560,180.00
- NERV N/A
- Revenue This Year
- HUSA N/A
- NERV N/A
- Revenue Next Year
- HUSA N/A
- NERV N/A
- P/E Ratio
- HUSA N/A
- NERV $9.21
- Revenue Growth
- HUSA N/A
- NERV N/A
- 52 Week Low
- HUSA $0.50
- NERV $1.15
- 52 Week High
- HUSA $3.20
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- HUSA 35.97
- NERV 57.59
- Support Level
- HUSA $0.52
- NERV $1.52
- Resistance Level
- HUSA $0.59
- NERV $1.81
- Average True Range (ATR)
- HUSA 0.07
- NERV 0.17
- MACD
- HUSA 0.02
- NERV 0.04
- Stochastic Oscillator
- HUSA 51.05
- NERV 90.91
About HUSA Houston American Energy Corporation
Houston American Energy Corp is an independent oil and gas company focused on the development, exploration, exploitation, acquisition, and production of natural gas and crude oil properties. Its properties, and operations, are in the U.S. Permian Basin, the U.S. Gulf Coast region, particularly Louisiana, and the South American country of Colombia. Geographically, the company currently has operations in two geographical areas, the United States, from where it derives maximum revenue, and Colombia.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.